EVER Pharma gains EU Marketing Authorization for Trabectedin
Trabectedin (in 0.25MG and 1MG vial sizes)
EVER Pharma announces the EU-wide marketing authorization of Trabectedin (in 0.25MG and 1MG vial sizes) for the treatment of advanced soft tissue sarcoma and ovarian cancer
Soft tissue sarcoma (STS) and ovarian cancer are rare forms of cancer affecting in total around 150,000 patients in the European Union. Trabectedin is recommended for treating advanced STS. It is also an important treatment option for patients with relapsed ovarian cancer.
“Rare and late stage forms of cancer are often poorly served when it comes to available therapeutics. EVER Pharma is pleased to make this complex and technically challenging product available to patients living with these cancers. This is part of our commitment to improving patient access to essential pharmaceuticals” said Georges Kahwati, General Manager of EVER Pharma.
The European authorization of EVER Pharma’s Trabectedin is another important addition to the rapidly expanding EVER portfolio of specialty injectable products. The product is planned for roll out into major markets globally.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance